Dermoscopy Two Step Algorithm vs Melanoma Prognostic Instrument

This app is intended to help you interpret the dermoscopic patterns seen with your dermatoscope. You will be asked a series of questions that will lead you to the most probable diagnosis. This app also contains over 80 photos and charts to help you in your diagnosis. No internet connection needed to view the full app. It is all ready for super quick image and information retrieval. There are also 50 interactive cases to solve. Each case starts with a clinical and dermoscopic image and ends with a labelled dermoscopic image pointing out critical structures. This app is based on the 2 step algorithm with the first step involving the determination of whether the lesion is a melanocytic. Melanocytic lesions will be divided into nevi or lesions with varying levels of suspicion for melanoma based on melanoma specific patterns and common nevi patterns. Non-melanocytic lesions will be analyzed to determine if they are suspicious for basal cell carcinoma or squamous cell carcinoma. Common benign lesions such as dermatofibroma, seborrheic keratoses and hemangiomas will be positively identified to avoid unnecessary biopsies. This app will increase your ability to detect skin cancers with greater accuracy thereby decreasing unnecessary biopsies and missing less early melanomas and nonmelanoma skin cancers. Check out https://usatinemedia.com to learn more and watch a video demo of this app narrated by Dr. Richard P. Usatine. Authors: Ashfaq A. Marghoob, MD Memorial Sloan-Kettering Cancer Center New York, New York Richard P. Usatine, MD University of Texas Health Science Center San Antonio, Texas Natalia Jaimes, MD Aurora Skin Cancer Center and Universidad Pontificia Bolivariana Medellin, Colombia To learn more dermoscopy from these authors, see www.americandermoscopy.com. Disclaimer: This app is intended for the education of healthcare professionals and not as a diagnostic and treatment reference for the general population. Disclaimer: While this app may help you in rendering a correct diagnosis, it is not intended to entirely replace the findings on patient history and physical examination including examination of the lesion with side lighting and touch. The final diagnosis rests on properly assimilating the information gained from the patient history, thorough naked eye physical examination, and meticulous dermoscopic inspection of the lesion. 3Gen, Inc. is the sponsor of this app. Visit www.dermlite.com to see their complete line of skin imaging devices. Developed by Usatine Media Richard P. Usatine, MD, Co-President, Professor of Family & Community Medicine, Professor of Dermatology and Cutaneous Surgery, University of Texas Health San Antonio Peter Erickson, Co-President, Lead Software Developer

The Prognostic Instrument for Melanoma (version 2.0) is a population-based tool that is based on a large amount of clinical and histopathological data from the Swedish quality registry for cutaneous melanoma (SweMR). In this updated version of the instrument, data from more than 70,000 patients with primary malignant melanoma between 1990 and 2021 have been included. Through a combination of several independent risk factors, melanoma-specific survival has been analysed for a variety of risk groups. The instrument calculates survival 1 to 10 years after diagnosis and provides an analysis at group level but can never provide an exact individual prognosis. The results are presented with 95% confidence intervals. The prognostic instrument has been designed for use by physicians in relation to patients with primary malignant melanoma. The analyses that form the basis of the instrument are performed on separate models for thin melanomas (≤ 1mm) and thicker melanomas (> 1mm) due to the fact that sentinel lymph node biopsy (SLNB) is generally not recommended for thin melanomas in Sweden. When choosing a thickness of 1 mm or less in the instrument, "Sentinel lymph node status" will not be included as a parameter.